Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3717
Name gastric adenocarcinoma
Definition A stomach carcinoma that derives_from epithelial cells of glandular origin.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer stomach cancer stomach carcinoma gastric adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00780494 Phase II Bevacizumab + Capecitabine + Carboplatin Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma Completed USA 0
NCT01191697 Phase II Bevacizumab + Trastuzumab Capecitabine + Oxaliplatin CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer Active, not recruiting USA 0
NCT01450696 Phase III Capecitabine + Cisplatin + Trastuzumab HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer Terminated USA | ITA | GBR | ESP | DEU | AUS 19
NCT01526473 Phase I AVX901 A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Completed USA 0
NCT01662869 Phase III Onartuzumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 15
NCT01747551 Phase II Aflibercept Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Completed USA 0
NCT01774786 Phase III Pertuzumab Capecitabine + Cisplatin + Fluorouracil + Trastuzumab A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed USA | ITA | ESP | DEU | CAN | BEL | AUT | AUS 24
NCT01774851 Phase II MM-111 + Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Terminated USA 0
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01896531 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ipatasertib A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Completed USA | ITA | GBR | FRA | ESP | DEU 5
NCT01913639 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer Completed USA 0
NCT02016534 Phase II AMG 337 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 8
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02065765 Phase II Ramucirumab International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer No longer available DEU | AUT 3
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed USA 0
NCT02178956 Phase III Napabucasin Paclitaxel A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT02205047 Phase II Capecitabine + Cisplatin Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Capecitabine + Cisplatin + Pertuzumab + Trastuzumab Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION) Active, not recruiting ITA | GBR | FRA | ESP | DEU | BEL 7
NCT02213289 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Docetaxel + Fluorouracil Trastuzumab Fluorouracil + Irinotecan + Leucovorin Rilotumumab PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Completed USA 0
NCT02234596 Phase II Nintedanib Nintedanib in Patients With Advanced Esophagogastric Cancer Completed USA 0
NCT02241720 Phase II Regorafenib Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers Terminated USA 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 2
NCT02283359 Phase I Irinotecan + Selinexor Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus Terminated USA 0
NCT02317991 Phase II Nab-paclitaxel + Ramucirumab Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Completed USA 0
NCT02335411 Phase II Cisplatin + Fluorouracil + Pembrolizumab Pembrolizumab A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Completed 0
NCT02340975 Phase Ib/II Durvalumab Tremelimumab A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma Completed USA | CAN 4
NCT02443324 Phase I Pembrolizumab + Ramucirumab A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium Completed USA | GBR | FRA | ESP | DEU 1
NCT02494583 Phase III Capecitabine Cisplatin + Fluorouracil Pembrolizumab Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Completed 0
NCT02500043 Phase III Trifluridine-tipiracil hydrochloride Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 10
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Completed USA | ESP | DEU | BEL | AUT | AUS 3
NCT02514551 Phase II Paclitaxel Ramucirumab A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Completed USA | ITA | ESP | DEU | CAN | BEL 5
NCT02545504 Phase III Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Andecaliximab GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 8
NCT02551055 Phase I Docetaxel Paclitaxel Alisertib Mivavotinib Serabelisib MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated USA | ESP 0
NCT02563548 Phase I PEGPH20 + Pembrolizumab Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab Completed USA 0
NCT02564900 Phase I Trastuzumab deruxtecan Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Completed USA 1
NCT02572687 Phase I Durvalumab + Ramucirumab A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies Completed USA | ITA | FRA | ESP | DEU 3
NCT02574663 Phase I Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Completed USA 0
NCT02578368 Phase III Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5) Active, not recruiting DEU 0
NCT02597036 Phase I LY3127804 Ramucirumab A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | BEL 0
NCT02599324 Phase Ib/II Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Completed USA | GBR | ESP 1
NCT02625610 Phase III Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Avelumab Capecitabine + Oxaliplatin Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT02625623 Phase III Avelumab Paclitaxel Irinotecan Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed USA | ITA | FRA | ESP | DEU | BEL | AUS 3
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02675946 Phase I CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Unknown status USA 1
NCT02678182 Phase II Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) Recruiting GBR 0
NCT02689284 Phase Ib/II Margetuximab-cmkb + Pembrolizumab Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer Completed USA | CAN 3
NCT02715531 Phase I Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors Completed USA | AUS 5
NCT02773524 Phase III Regorafenib A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) Unknown status USA | CAN | AUS 4
NCT02864381 Phase II Nivolumab Andecaliximab + Nivolumab GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Completed USA | ITA | GBR | FRA | ESP | BEL | AUS 2
NCT02908451 Phase I AbGn-107 A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer Terminated USA 1
NCT02918162 Phase II Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab Perioperative Chemo and Pembrolizumab in Gastric Cancer Completed USA 0
NCT02934464 Phase III Paclitaxel + Ramucirumab Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (ARMANI) Unknown status ITA 0
NCT02943603 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach Withdrawn USA 0
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Completed USA 0
NCT03042611 Phase III Rivoceranib Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer Completed USA | ITA | GBR | FRA | DEU 7
NCT03064490 Phase II Carboplatin + Paclitaxel + Pembrolizumab Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) Completed USA 0
NCT03081143 Phase II Paclitaxel + Ramucirumab Fluorouracil + Irinotecan + Leucovorin + Ramucirumab Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (RAMIRIS) Recruiting ITA | DEU | AUT 0
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Completed USA 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 4
NCT03122548 Phase II CRS-207 + Pembrolizumab Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers Terminated USA 0
NCT03141034 Phase II Irinotecan + Ramucirumab Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Completed USA 0
NCT03193918 Phase I Crenolanib + Paclitaxel + Ramucirumab Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma Completed USA 0
NCT03196232 Phase II Epacadostat + Pembrolizumab Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Completed USA 0
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Unknown status USA 0
NCT03221426 Phase III Capecitabine + Cisplatin Capecitabine + Cisplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Active, not recruiting USA | ITA | GBR | FRA | DEU | CAN | BEL 17
NCT03257163 Phase II Capecitabine + Pembrolizumab Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Recruiting USA 0
NCT03281369 Phase Ib/II Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) Active, not recruiting USA | GBR | ESP | AUS 3
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) Recruiting USA 0
NCT03321630 Phase II Lenvatinib + Pembrolizumab A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies Completed USA 0
NCT03365791 Phase II Ieramilimab Spartalizumab PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies Completed USA 0
NCT03368963 Phase Ib/II Liposomal irinotecan + Trifluridine-tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting USA 0
NCT03396211 Phase I Nivolumab + Rivoceranib Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Completed USA 0
NCT03407976 Phase Ib/II Pembrolizumab + Rivoceranib Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Terminated USA 0
NCT03421288 Phase II Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (DANTE) Recruiting DEU 1
NCT03427814 Phase III Pamiparib Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer Completed USA | GBR | FRA | ESP | BEL | AUS 11
NCT03488667 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma Active, not recruiting USA 0
NCT03504397 Phase III Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT03505320 Phase II Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Pembrolizumab + Zolbetuximab A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO) Recruiting USA | ITA | FRA 3
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03539822 Phase I Cabozantinib + Durvalumab Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) Active, not recruiting USA 0
NCT03588039 Phase I Oraxol + Pembrolizumab Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA 0
NCT03615326 Phase III Oxaliplatin + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 13
NCT03627728 Phase II Regorafenib Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer (a-MANTRA) Recruiting ITA 0
NCT03641313 Phase II Berzosertib + Irinotecan Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer Active, not recruiting USA 0
NCT03653507 Phase III Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Zolbetuximab A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW) Active, not recruiting USA | GBR | ESP | CAN 14
NCT03666273 Phase I BAY1905254 BAY1905254 + Pembrolizumab A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 Active, not recruiting USA 0
NCT03675737 Phase III Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 25
NCT03686488 Phase II Ramucirumab + Trifluridine-tipiracil hydrochloride TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Active, not recruiting USA 0
NCT03694522 Phase II Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 10
NCT03697304 Phase II Ezabenlimab Miptenalimab Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. Active, not recruiting USA | GBR | CAN 0
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting USA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | GBR | FRA | ESP 2
NCT03735290 Phase Ib/II Pembrolizumab Intuvax + Pembrolizumab A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) Terminated USA 0
NCT03739801 Phase Ib/II Liposomal irinotecan + Ramucirumab MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Withdrawn USA 0
NCT03752398 Phase I Izuralimab A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) Active, not recruiting USA 0
NCT03760822 Phase II Paclitaxel + Ramucirumab Ramucirumab Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE) Active, not recruiting FRA 0
NCT03776487 Phase Ib/II Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer Active, not recruiting USA 0
NCT03777657 Phase III Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Active, not recruiting USA | ITA | GBR | FRA | ESP 8
NCT03783936 Phase II Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Completed USA 0
NCT03809624 Phase II INBRX-105 INBRX-105 + Pembrolizumab Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) Recruiting USA 0
NCT03840967 Phase II Niraparib A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Active, not recruiting USA 0
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Completed USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Active, not recruiting USA | ESP | CAN | BEL 0
NCT03918499 Phase Ib/II Cyclophosphamide + IRX-2 + Pembrolizumab IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer Completed USA 0
NCT03954704 Phase I Fluorouracil + GS-1423 + Leucovorin + Oxaliplatin GS-1423 Study of GS-1423 in Participants With Advanced Solid Tumors Terminated USA 0
NCT03959293 Phase II Durvalumab + Fluorouracil + Irinotecan + Leucovorin + Tremelimumab Durvalumab + Fluorouracil + Irinotecan + Leucovorin Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma Active, not recruiting FRA 0
NCT03964233 Phase I BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) Recruiting USA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT03966118 Phase II Avelumab + Paclitaxel + Ramucirumab Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma (AIO-STO-0218) Unknown status DEU 0
NCT03995017 Phase Ib/II Ramucirumab + Rucaparib Nivolumab + Ramucirumab + Rucaparib Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME) Active, not recruiting USA 0
NCT03997448 Phase II Abemaciclib + Pembrolizumab Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 Terminated USA 0
NCT04006262 Phase II Ipilimumab + Nivolumab Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA) Recruiting FRA 0
NCT04007744 Phase I Pembrolizumab + Sonidegib Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Recruiting USA 0
NCT04021108 Phase II Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Active, not recruiting USA 0
NCT04029922 Phase I MT-5111 Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) Terminated USA | AUS 1
NCT04032704 Phase II Ladiratuzumab vedotin A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Terminated USA | ITA | GBR | AUS 2
NCT04041310 Phase I GAd-209-FSP + MVA-209-FSP Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Recruiting USA | ITA | GBR | ESP | CAN | BEL 0
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA | GBR 0
NCT04069273 Phase II Paclitaxel + Ramucirumab Paclitaxel + Pembrolizumab + Ramucirumab Pembrolizumab Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) (SEQUEL) Recruiting USA 0
NCT04074343 Phase I Irinotecan + Trifluridine-tipiracil hydrochloride TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma Completed USA 0
NCT04089904 Phase II Pembrolizumab Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma Completed USA 0
NCT04099641 Phase II Bavituximab + Pembrolizumab An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients Completed USA | GBR 2
NCT04111172 Phase II Ad5.F35-hGCC-PADRE Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies Suspended USA 0
NCT04112498 Phase I Nivolumab + Relatlimab + rHuPH20 A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab Completed USA 0
NCT04114136 Phase II Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Recruiting USA 0
NCT04117958 Phase I AMG 199 Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers Terminated USA | FRA | ESP | DEU | AUT 4
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Completed USA | FRA | ESP | DEU | BEL 3
NCT04152499 Phase Ib/II SKB264 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) Recruiting USA 1
NCT04164979 Phase II Cabozantinib + Pembrolizumab Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma Active, not recruiting USA 0
NCT04171141 Phase I PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. Terminated USA | AUS 1
NCT04198766 Phase I INBRX-106 INBRX-106 + Pembrolizumab Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Recruiting USA 0
NCT04260191 Phase I AMG 910 Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma Terminated USA | FRA | ESP | DEU | AUT 4
NCT04276376 Phase II Atezolizumab + Rucaparib Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) Suspended FRA 0
NCT04363801 Phase II DKN-01 + Tislelizumab Capecitabine + DKN-01 + Oxaliplatin + Tislelizumab A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish) Active, not recruiting USA | DEU 1
NCT04379596 Phase II Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Oxaliplatin + Trastuzumab Fluorouracil + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Durvalumab + Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab deruxtecan Pembrolizumab + Trastuzumab deruxtecan Capecitabine + Oxaliplatin + Trastuzumab deruxtecan Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan Durvalumab + Fluorouracil + Trastuzumab deruxtecan Capecitabine + Durvalumab + Trastuzumab deruxtecan Capecitabine + Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan Capecitabine + Fluorouracil + MEDI5752 + Trastuzumab deruxtecan Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Cisplatin + Trastuzumab Trastuzumab deruxtecan Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03) Recruiting USA | ITA | GBR | ESP | DEU | CAN 8
NCT04393298 Phase Ib/II UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors Active, not recruiting USA | GBR 0
NCT04404595 Phase Ib/II CT041 Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers Active, not recruiting USA | CAN 0
NCT04430738 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Recruiting USA 1
NCT04442126 Phase Ib/II NM21-1480 A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Terminated USA | ESP 1
NCT04450732 Phase I GQ1001 Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Recruiting USA | AUS 1
NCT04499924 Phase II Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib Paclitaxel + Ramucirumab + Tucatinib Paclitaxel + Ramucirumab Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02) Active, not recruiting USA | GBR | CAN | AUS 2
NCT04510285 Phase II Pembrolizumab + Trastuzumab A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection Terminated USA 0
NCT04517747 Phase 0 Ramucirumab + Trifluridine-tipiracil hydrochloride Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (RE-ExPEL) Completed DEU 0
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Completed USA | ITA | FRA | ESP | DEU | CAN 8
NCT04579757 Phase Ib/II Surufatinib + Tislelizumab Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04592913 Phase III Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT04604132 Phase Ib/II Atezolizumab + Derazantinib Derazantinib + Paclitaxel + Ramucirumab Derazantinib Paclitaxel + Ramucirumab Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03) Terminated USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT04660760 Phase II Paclitaxel + Ramucirumab Ramucirumab + Trifluridine-tipiracil hydrochloride Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer Recruiting USA 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04704934 Phase III Paclitaxel + Ramucirumab Trastuzumab deruxtecan Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Recruiting ITA | GBR | FRA | ESP | DEU | BEL 18
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04735796 Phase I LM-102 Study of LM-102 in Subjects in Advanced Tumors Terminated USA 0
NCT04739202 Phase II Atezolizumab + Bevacizumab Atezolizumab + Ipatasertib Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST) Unknown status FRA 0
NCT04757363 Phase II Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Regorafenib A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer Active, not recruiting USA 0
NCT04777994 Phase I ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors Recruiting USA | FRA | ESP 3
NCT04779151 Phase II Dostarlimab-gxly + Niraparib Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) Recruiting FRA 0
NCT04798781 Phase II Pembrolizumab + Telatinib Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma Active, not recruiting USA 0
NCT04834778 Phase I HC-5404-FU A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) Completed USA 0
NCT04879368 Phase III Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) Recruiting USA | ITA | ESP | DEU | AUT | AUS 3
NCT05001347 Phase II Uliledlimab A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors Completed USA 0
NCT05001516 Phase Ib/II TPX-4589 Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors Active, not recruiting USA 0
NCT05002127 Phase II Paclitaxel + Ramucirumab + Trastuzumab Paclitaxel + Ramucirumab Evorpacept + Paclitaxel + Ramucirumab + Trastuzumab A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Recruiting USA | ITA | GBR | FRA | ESP | BEL 5
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 1
NCT05041153 Phase I Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma Recruiting USA 0
NCT05052801 Phase III Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101) Recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 30
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05071053 Phase II Ramucirumab + SAR408701 Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (CARMEN-GC01) Active, not recruiting ESP | BEL 4
NCT05101070 Phase Ib/II Pembrolizumab + S-531011 Pembrolizumab S-531011 S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) Recruiting USA 1
NCT05102214 Phase Ib/II HLX301 HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors Recruiting AUS 0
NCT05109442 Phase Ib/II AFM24 + Atezolizumab Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers Recruiting USA | GBR | ESP 2
NCT05111626 Phase I Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Bemarituzumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT05128487 Phase Ib/II NDI-101150 NDI-101150 + Pembrolizumab A Study of NDI 1150-101 in Patients With Solid Tumors Recruiting USA 0
NCT05135845 Phase II Capmatinib + Spartalizumab Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma (METIMGAST) Suspended FRA 0
NCT05144698 Phase II RAPA-201 RAPA-201 Therapy of Solid Tumors Recruiting USA 0
NCT05152147 Phase III Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + ZW25 Cisplatin + Fluorouracil + Tislelizumab + ZW25 Capecitabine + Oxaliplatin + Tislelizumab + ZW25 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) Recruiting ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 26
NCT05153304 Phase Ib/II Ipilimumab + Nivolumab A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers Not yet recruiting USA 0
NCT05177133 Phase II Capecitabine + Oxaliplatin + Retifanlimab Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) (AuspiCiOus) Recruiting 1
NCT05187182 Phase I CA-4948 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer Recruiting USA 0
NCT05190445 Phase II PRS-343 + Tucatinib Paclitaxel + PRS-343 + Ramucirumab Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma Active, not recruiting USA 1
NCT05207722 Phase Ib/II Aldesleukin + CYNK-101 + Pembrolizumab + Trastuzumab CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Active, not recruiting USA 0
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Recruiting USA 0
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05274048 Phase I Neratinib + Trastuzumab deruxtecan Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients Recruiting USA 0
NCT05311176 Phase II IMU-131 + Paclitaxel + Ramucirumab IMU-131 + Pembrolizumab A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) (nextHERIZON) Active, not recruiting AUS 1
NCT05329766 Phase II AB680 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Zimberelimab Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) Recruiting USA | FRA | CAN 2
NCT05365581 Phase I ASP2138 A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer Recruiting USA 2
NCT05379972 Phase II Olaparib + Pembrolizumab Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers Recruiting USA 0
NCT05411133 Phase I ARB202 + Atezolizumab ARB202 Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients Recruiting AUS 1
NCT05417321 Phase Ib/II HB0036 A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors Recruiting USA 1
NCT05427487 Phase I IVX037 Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours Recruiting AUS 0
NCT05429762 Phase I SAR408701 Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) Active, not recruiting USA | FRA | ESP | BEL 1
NCT05458219 Phase I IBI343 A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Recruiting AUS 0
NCT05476796 Phase II Fluorouracil + Leucovorin + Oxaliplatin Nivolumab + Oxaliplatin + Trifluridine-tipiracil hydrochloride Oxaliplatin + Trifluridine-tipiracil hydrochloride Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer (LOGICAN) Recruiting FRA 0
NCT05482516 Phase III Atezolizumab + Bevacizumab Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) Recruiting USA 0
NCT05482893 Phase I PT886 PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) Recruiting USA 0
NCT05504720 Phase II Pembrolizumab + Trastuzumab Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma Recruiting DEU 0
NCT05525286 Phase Ib/II Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + SOT102 Gemcitabine + Nab-paclitaxel + SOT102 SOT102 Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) Suspended USA | FRA | ESP | BEL 1
NCT05539430 Phase I LB1908 Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma Recruiting USA 0
NCT05555251 Phase Ib/II BI-1607 + Trastuzumab BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST) Active, not recruiting GBR | ESP | DEU 0
NCT05568095 Phase III AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Capecitabine + Oxaliplatin + Zimberelimab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 22
NCT05614102 Phase I BAY2965501 A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | BEL 3
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Recruiting ESP | BEL 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05702229 Phase II AZD2936 + Fluorouracil + Leucovorin + Oxaliplatin AZD2936 + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + MEDI5752 + Oxaliplatin Capecitabine + MEDI5752 + Oxaliplatin Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting USA | GBR | ESP 4
NCT05802056 Phase I Aldesleukin + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Aldesleukin in Combination With Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer With Peritoneal Metastasis, CONTROL Study Recruiting USA 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05836584 Phase II Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab Atezolizumab + Capecitabine + Oxaliplatin Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer Recruiting USA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05859477 Phase II Capecitabine + Nivolumab + Oxaliplatin Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2) Recruiting USA 0
NCT05862324 Phase Ib/II TAC01-CLDN18.2 TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) Recruiting USA | CAN 0
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT05965479 Phase II Trastuzumab deruxtecan Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER) Not yet recruiting GBR 0
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT06005493 Phase Ib/II AZD5863 Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors Recruiting USA | GBR 5
NCT06038578 Phase II Paclitaxel + Ramucirumab + TRK-950 Paclitaxel + Ramucirumab A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer Recruiting USA 1
NCT06048081 Expanded access Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Capecitabine + Oxaliplatin + Zolbetuximab Early Access Program for Zolbetuximab Available USA 0
NCT06056024 Phase I BI 3706674 A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus Recruiting USA 2
NCT06059495 Phase II Dostarlimab-gxly Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (DEWI) Recruiting FRA 0
NCT06109467 Phase II Fluorouracil + Leucovorin + Neratinib + Oxaliplatin + Pembrolizumab + Trastuzumab Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer Recruiting USA 0
NCT06123338 Phase II Pembrolizumab + Trastuzumab A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer Recruiting USA 0
NCT06157892 Phase Ib/II Disitamab vedotin + Tucatinib Disitamab vedotin A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors Recruiting USA 0
NCT06171789 Phase Ib/II PRO1107 PRO1107 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06219941 Phase II AZD0901 + Irinotecan AZD0901 + Liposomal irinotecan AZD0901 + Leucovorin AZD0901 + Fluorouracil AZD0901 + Gemcitabine AZD0901 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Recruiting USA | GBR | ESP | CAN | AUS 7
NCT06251973 Phase II AgenT-797 + Balstilimab + Botensilimab + Paclitaxel + Ramucirumab A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer Recruiting USA 0